About NIH
The National Institute of Health is a government agency
leading public health and medical research in South Korea
About NIH
Browse the latest research papers,
patents, and technological achievements
About NIH
Recent news from the National Institute of Health
Official Announcement on International Collaborative Research for One Health Antimicrobial Resistance Integrative Surveillance (Sponsored by the Korea National Institute of Health, KDCA)
Update 14.07.2026
Korea National Institute of Health (KNIH)
2026 Grant Program
Official Announcement on International Collaborative Research for One Health Antimicrobial Resistance Integrative Surveillance (Sponsored by the Korea National Institute of Health, KDCA)
1. Background and Rationale
The Korea National Institute of Health (KNIH), a research institute of the Korea Disease Control and Prevention Agency (KDCA), is committed to strengthening evidence-based responses to antimicrobial resistance (AMR) through research, surveillance, and international collaboration.
AMR is a growing global public health threat affecting humans, animals, and the environment. Effective surveillance under a One Health framework is essential to understand the transmission and dissemination of resistant bacteria across sectors. While several countries have established sector-specific AMR monitoring systems, integrated One Health surveillance remains limited in many settings.
This project aims to strengthen One Health AMR surveillance capacity through international collaboration and to generate evidence on the occurrence and transmission of antimicrobial-resistant bacteria across human, animal, and environmental sectors. The study findings are expected to support national and regional AMR control strategies and contribute to global One Health AMR surveillance initiatives.
2. Project Details
2.1 Title
International Collaborative Research for One Health Antimicrobial Resistance Integrative Surveillance
2.2 Project Duration
Three years (2026–2028)
- Year 1: Contract date – December 31, 2026
- Year 2: January 1, 2027 – December 31, 2027
- Year 3: January 1, 2028 – December 31, 2028
2.3. Funding
The annual fund will be approximately 99,200 USD (150,000,000 KRW).
2.4 Countries
Asian countries with a demonstrated need for strengthening One Health AMR surveillance capacity.
2.5. Eligibility of Applicants
The Principal Investigator should hold at least one of the Ph.D., M.D., or equivalent qualification.
2.6 Research Areas of Focus
2.6.1. Objective
To establish and implement an integrated One Health AMR surveillance system encompassing human, animal, and environmental sectors.
- Specific Objectives:
a. To conduct AMR surveillance in human, animal, and environmental samples using harmonized protocols.
b. To characterize antimicrobial-resistant bacteria using phenotypic and genomic approaches.
c. To evaluate potential transmission pathways of AMR across sectors under a One Health framework.
d. To strengthen local capacity for AMR surveillance, laboratory analysis, and data interpretation.
2.6.2. Study Design and Methodology
2.6.2.1. Establishment of a One Health AMR Surveillance Network
The study will establish a multisectoral surveillance network involving human health, animal health, and environmental sectors. Participating institutions will collaborate to implement harmonized sampling, laboratory testing, and data analysis procedures under a One Health framework.
2.6.2.2. Sample Collection and Surveillance Activities
Samples will be collected from human, animal, and environmental sectors over a two-year study period.
- Human sector
* Stool samples and/or bacterial isolates will be collected from clinical patients and community populations.
* More than 150 human samples will be included.
- Animal sector
* Samples will be collected from poultry and slaughterhouse environments.
* Chicken carcasses and environmental samples from slaughterhouse facilities will be included.
* More than 120 animal-related samples will be collected.
- Environmental sector
* Samples will be collected from river systems and hospital wastewater.
* River upstream, river downstream, and hospital effluent sites will be included.
* More than 90 environmental samples will be collected.
- Total sample size
* A minimum of 360 samples will be collected across all sectors during the study period.
2.6.2.3. Laboratory Detection and Characterization of Antimicrobial-Resistant Bacteria
- Samples will be processed using standardized microbiological procedures for the isolation of indicator bacteria, including Escherichia coli.
- Selective culture methods will be applied to identify isolates with reduced susceptibility to third-generation cephalosporins and carbapenems.
- Species identification will be performed using MALDI-TOF MS or equivalent methods.
- Antimicrobial susceptibility testing will be conducted according to CLSI guidelines using disk diffusion and/or broth microdilution methods.
2.6.2.4. Detection of Antimicrobial Resistance Determinants
- Isolates demonstrating resistance phenotypes will undergo molecular characterization.
- Resistance genes associated with extended-spectrum β-lactamases (ESBLs), plasmid-mediated AmpC β-lactamases (PABLs), carbapenemases, and qnrA will be detected using PCR and sequencing methods.
- Target genes may be adapted according to local epidemiological priorities.
2.6.2.5. Whole-Genome Sequencing and Metagenomic Analysis
- Whole-genome sequencing (WGS) will be performed on selected antimicrobial-resistant isolates.
- Genomic analyses will include resistance gene identification, molecular epidemiology, phylogenetic analysis, and comparative genomic investigations.
- Representative samples from human, animal, and environmental sectors will be selected for metagenomic analysis.
- Metagenomic analyses will be conducted to characterize the resistome and microbial community composition across sectors.
2.6.2.6. Analysis Protocol
Data analysis will be conducted collaboratively using harmonized protocols provided by the Korea National Institute of Health (KNIH) and participating institutions.
- The analysis will include:
* Prevalence and distribution of antimicrobial resistance
* Distribution of antimicrobial resistance genes
* Genomic relatedness among isolates from different sectors
* Characterization of environmental resistomes
* Identification of potential transmission pathways under a One Health framework
* Comparative analysis across human, animal, and environmental sectors
3. Reporting System
The application should be submitted in English via email before June 30, 2026.
Applicants must submit:
- Letter of Intent
- Research Proposal
- Institutional Profile
- Curriculum Vitae of Principal Investigator
4. Key Dates
- Application opens on July 15, 2026
- Application due by July 20, 2026
* Letter of intent and project proposal should be submitted via email (ejyoon3@korea.kr)
*Confirmation of your submission will be sent via email within three days.
- Review due July 23, 2026
- Result notification (via email) July 25, 2026
5. Contact
Division of Antimicrobial Resistance Research
Center for Infectious Disease Research
National Institute of Health
Korea Disease Control and Prevention Agency
Republic of Korea
TEL: +82-43-719-8242
Email: ejyoon3@korea.kr